SPDB-DM4 (CAS: 1626359-62-3)
Overview: SPDB-DM4 is an advanced drug-linker conjugate for Antibody-Drug Conjugates (ADCs) in cancer therapy. It combines DM4, a potent tubulin inhibitor, with the SPDB linker, enabling precise targeting. This setup delivers the cytotoxic drug directly to cancer cells, reducing harm to healthy tissue and maximizing anti-tumor e
Applications:
- Cancer Research: Crucial in cancer research, especially for the development of Antibody-Drug Conjugates (ADCs).
- Next-Generation Drug Delivery: Its superior conjugation efficiency and stability make it ideal for designing advanced drug delivery systems.
- Microtubule Dynamics: The DM4 payload disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells.
- Targeted Therapies: Therapies that specifically target cancer cells, minimizing damage to healthy tissues.
- New Cancer Treatment Strategies: It helps explore innovative approaches to treating various malignancies.
- ADC Stability and Efficacy: Key role in refining the stability and effectiveness of ADCs for improved therapeutic outcomes.
Key Features:
- DM4 Payload: Inhibits tubulin, halting cancer cell division.
- SPDB Linker: Ensures targeted delivery to cancer cells.
- Anti-Tumor Activity: Enhances impact on tumors while sparing healthy cells.
SPDB-DM4 accelerates cancer therapy research and improves ADC design. It is crucial for developing more effective, targeted cancer treatments.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
